We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Vienna, Austria

ESTRO 2025

Session

Sunday
May 04
15:15 - 16:15
Stolz 1
Genito-urinary 2
Gokhan Ozyigit, Turkey;
Miloš Grujić, Serbia
Mini-Orals are presented at one of the sessions scheduled in the two mini-oral theatres. Each author will present a 4-slide PowerPoint orally for 4 minutes, followed by 3 minutes for discussion. Sessions will be recorded and made available via the online platform and mobile app.
Mini-Orals
Clinical
15:15 - 15:22
Genomic landscape of hypoxia in bladder cancer
Amen Shamim, United Kingdom
E25-4290
15:22 - 15:29
PERSIAN TRIAL (NCT03449719): Apalutamide and stereotactic body radiation therapy in patients affected by hormone-sensitive prostate cancer
Giulio Francolini, Italy
E25-940
15:29 - 15:36
Pelvic ultra-hypofractionated vs conventionally fractionated IMRT with HDR brachytherapy boost in prostate cancer: PCS-XI trial interim (NCT05820633)
François Fabi, Canada
E25-2249
15:36 - 15:43
Prostate-specific antigen bounce after prostate ultra-hypofractionation: associations with 5-year outcomes in the phase 3 trial HYPO-RT-PC
Astrid E Persson, Sweden
E25-9
15:43 - 15:50
Liquid biopsy-based molecular characterization of oligometastatic state in prostate cancer: the RADIOSA trial (NCT03940235) biology task
Giulia Marvaso, Italy
E25-1872
15:50 - 15:57
Stereotactic body radiotherapy vs HDR brachytherapy for prostate cancer: the SHERBET individual patient data meta-analysis of five prospective trials
Andrew Loblaw, Canada
E25-1033
15:57 - 16:04
Long-Term Results of Radiotherapy with or without Focal Boost in Patients with Localized Prostate Cancer: A Propensity Score Match Analysis
Cem Onal, Turkey
E25-372
16:04 - 16:11
Updated Results of the Multicentric Post-Prostatectomy Ablative Radiation Therapy (POPART) Trial: Predictors of Toxicities and Oncological Outcomes
Federica Ferrario, Italy
E25-3855